Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 48 studies | 46% ± 20% | |
fibroblast | 44 studies | 41% ± 19% | |
pericyte | 39 studies | 62% ± 26% | |
smooth muscle cell | 35 studies | 48% ± 17% | |
endothelial cell of lymphatic vessel | 18 studies | 41% ± 15% | |
capillary endothelial cell | 15 studies | 47% ± 21% | |
myofibroblast cell | 15 studies | 52% ± 19% | |
endothelial cell of vascular tree | 14 studies | 31% ± 12% | |
connective tissue cell | 13 studies | 39% ± 18% | |
vein endothelial cell | 13 studies | 38% ± 16% | |
type I pneumocyte | 11 studies | 43% ± 12% | |
adipocyte | 10 studies | 80% ± 12% | |
endothelial cell of artery | 9 studies | 38% ± 24% | |
astrocyte | 8 studies | 22% ± 8% | |
cardiac muscle cell | 6 studies | 34% ± 12% | |
GABAergic neuron | 5 studies | 28% ± 8% | |
glomerular endothelial cell | 4 studies | 60% ± 4% | |
epithelial cell of proximal tubule | 4 studies | 28% ± 14% | |
epithelial cell | 4 studies | 37% ± 15% | |
kidney loop of Henle epithelial cell | 4 studies | 22% ± 6% | |
hepatic stellate cell | 3 studies | 59% ± 17% | |
abnormal cell | 3 studies | 38% ± 28% | |
neural crest cell | 3 studies | 34% ± 26% | |
extravillous trophoblast | 3 studies | 82% ± 9% | |
glial cell | 3 studies | 37% ± 14% | |
lymphocyte | 3 studies | 26% ± 4% | |
muscle cell | 3 studies | 77% ± 14% | |
glutamatergic neuron | 3 studies | 26% ± 7% | |
adventitial cell | 3 studies | 29% ± 7% | |
Schwann cell | 3 studies | 32% ± 6% | |
interneuron | 3 studies | 18% ± 4% | |
parietal epithelial cell | 3 studies | 51% ± 7% | |
myoepithelial cell | 3 studies | 44% ± 25% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 99% | 46045.59 | 456 / 459 | 97% | 85.59 | 1083 / 1118 |
lung | 100% | 53594.34 | 577 / 578 | 94% | 80.07 | 1086 / 1155 |
thymus | 98% | 24298.49 | 642 / 653 | 93% | 66.35 | 565 / 605 |
intestine | 93% | 54171.11 | 898 / 966 | 92% | 75.40 | 485 / 527 |
kidney | 87% | 19387.83 | 77 / 89 | 97% | 152.49 | 874 / 901 |
prostate | 93% | 38211.87 | 229 / 245 | 88% | 49.65 | 442 / 502 |
uterus | 99% | 45284.69 | 168 / 170 | 80% | 87.17 | 369 / 459 |
bladder | 90% | 54317.19 | 19 / 21 | 89% | 66.60 | 447 / 504 |
esophagus | 76% | 43102.32 | 1091 / 1445 | 97% | 99.45 | 177 / 183 |
skin | 67% | 14542.92 | 1213 / 1809 | 93% | 84.03 | 437 / 472 |
ovary | 71% | 13551.96 | 127 / 180 | 89% | 53.34 | 382 / 430 |
adrenal gland | 74% | 12691.43 | 191 / 258 | 83% | 78.59 | 192 / 230 |
stomach | 61% | 23927.21 | 218 / 359 | 95% | 88.61 | 272 / 286 |
pancreas | 17% | 2285.55 | 56 / 328 | 96% | 134.87 | 171 / 178 |
adipose | 100% | 65085.16 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 98240.53 | 1335 / 1335 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 23.06 | 1 / 1 |
spleen | 99% | 36845.34 | 239 / 241 | 0% | 0 | 0 / 0 |
heart | 92% | 20875.57 | 790 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 84% | 64.10 | 38 / 45 |
liver | 8% | 1242.54 | 18 / 226 | 66% | 39.66 | 266 / 406 |
lymph node | 0% | 0 | 0 / 0 | 62% | 30.46 | 18 / 29 |
brain | 1% | 149.60 | 25 / 2642 | 42% | 35.17 | 298 / 705 |
muscle | 32% | 4119.68 | 253 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 23% | 7.93 | 18 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0001525 | Biological process | angiogenesis |
GO_0071560 | Biological process | cellular response to transforming growth factor beta stimulus |
GO_0035987 | Biological process | endodermal cell differentiation |
GO_0030198 | Biological process | extracellular matrix organization |
GO_0038063 | Biological process | collagen-activated tyrosine kinase receptor signaling pathway |
GO_0014823 | Biological process | response to activity |
GO_0016525 | Biological process | negative regulation of angiogenesis |
GO_0006351 | Biological process | DNA-templated transcription |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0070062 | Cellular component | extracellular exosome |
GO_0062023 | Cellular component | collagen-containing extracellular matrix |
GO_0005587 | Cellular component | collagen type IV trimer |
GO_0005788 | Cellular component | endoplasmic reticulum lumen |
GO_0005604 | Cellular component | basement membrane |
GO_0030020 | Molecular function | extracellular matrix structural constituent conferring tensile strength |
GO_0060090 | Molecular function | molecular adaptor activity |
GO_0005201 | Molecular function | extracellular matrix structural constituent |
GO_0005515 | Molecular function | protein binding |
Gene name | COL4A2 |
Protein name | Collagen type IV alpha 2 chain Collagen alpha-2(IV) chain [Cleaved into: Canstatin] |
Synonyms | |
Description | FUNCTION: Type IV collagen is the major structural component of glomerular basement membranes (GBM), forming a 'chicken-wire' meshwork together with laminins, proteoglycans and entactin/nidogen.; FUNCTION: Canstatin, a cleavage product corresponding to the collagen alpha 2(IV) NC1 domain, possesses both anti-angiogenic and anti-tumor cell activity. It inhibits proliferation and migration of endothelial cells, reduces mitochondrial membrane potential, and induces apoptosis. Specifically induces Fas-dependent apoptosis and activates procaspase-8 and -9 activity. Ligand for alphavbeta3 and alphavbeta5 integrins. |
Accessions | A0A3B3IRV2 ENST00000649951.1 A0A3B3IT80 A0A3B3ITQ8 ENST00000619688.2 P08572 A0A3B3ITN7 ENST00000360467.7 ENST00000650540.1 ENST00000649101.1 A0A3B3IS47 A0A3B3IS04 A2A352 ENST00000480609.1 ENST00000617564.2 ENST00000494852.2 A0A087WY39 ENST00000400163.7 |